Loading
CDH6 is an adhesion protein from kidney development that reappears on ovarian and kidney cancers. This dossier gathers the 1 product (0 approved), 5 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
CDH6 is a type II cadherin and a fetal kidney marker.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Ovarian cancer | 65-85% | IHC, any expression | High-grade serous | Wikipedia |
| Renal cell carcinoma | 60-80% | IHC, any expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Phase 3 |
|---|---|
| ADC 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
REJOICE-Ovarian01 NCT06161025 | 2/3 | Recruiting | Platinum-resistant ovarian cancer, 1-3 prior lines: raludotatug deruxtecan (CDH6 ADC) vs physician's-choice chemotherapy | Phase 2 ORR 50.5%; phase 3 ongoing. | |
| 2 | Recruiting | KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) | - | ||
| 2 | Active | A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers | - | ||
| 2 | Active | REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors | - | ||
| 1/2 | Recruiting | A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With Advanced High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian02) | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CDH6" OR ABSTRACT:"CDH6") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDH6, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/cdh6.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cdh6.json. Licence CC BY-NC 4.0.